Valeant Pharmaceuticals International, Inc. (NYSE: VRX) responded to Allergan, Inc.'s (NYSE: AGN) rejection of Valeant's proposal to combine with Allergan ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE